Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Taiho to Cooperate in Doctor-Led Clinical Trial
December 6, 2011
- Takeda Sets Up Global Vaccine Business Company to Enhance Global Operations
December 6, 2011
- OncoTherapy Confirms Safety of Cancer Vaccine OCV-105 in PI Trial
December 6, 2011
- Eisai’s US Research Subsidiary Starts Full Operation
December 5, 2011
- Pfizer, MSD Issue Repeated Warnings for Improper Use of Pneumococcal Vaccines Prevnar, Pneumovax
December 5, 2011
- Teijin Pharma Gets Good Response for Feburic from Medical Institutions: President Arao
December 2, 2011
- Pfizer President Umeda Says Steady Performance for Lyrica, “Business Objectives Achieved”
December 2, 2011
- Bayer, Regeneron Initiate PIII Trial for VEGF Trap-Eye in China
December 2, 2011
- Takeda Announces Overflow of Contaminated Water at Shonan Research Center
December 2, 2011
- Nippon Shinyaku to Open Representative Office in Beijing
December 2, 2011
- DSP, Yoshitomiyakuhin to Terminate Copromotion Agreement for Antipsychotics Lonasen, Lullan
December 2, 2011
- Confusion Seen Temporarily Over FDA Approval for Lipitor Generic
December 2, 2011
- Generic Drug Makers to Continue Launching Generics of Major Drugs Even with 60% Rule
December 2, 2011
- Teva Receives Tentative Approval for Generic Lipitor in the US
December 2, 2011
- Fuji-Keizai Sees Domestic Biopharamaceutical Market Reaching Nearly ¥1 Trillion in 2015
December 1, 2011
- UK AstraZeneca CEO Brennan Says Investment in Japan, a “Very Important Market,” Will Continue
December 1, 2011
- Sandoz Files Application for Additional Indication, Dosage, Administration for Anticancer Drug Paclitaxel Based on Data in Public Domain
December 1, 2011
- I'rom HD Sells All I'rom Pharmaceutical Shares to Kyowa Pharmaceutical Industry
December 1, 2011
- DSP Files NDA for Fixed-Dose Combination of ARB Avapro (Irbesartan) / CCB Amlodin (Amlodipine)
December 1, 2011
- Ranbaxy Launches Generic Lipitor; Marketing Tie-up with Teva
December 1, 2011
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…